Comparing Asthma And COPD

R.W. appears with progressive difficulty getting his breath while doing simple tasks, and also having difficulty doing any manual work, complains of a cough, fatigue, and weight loss, and has been treated for three respiratory infections a year for the past 3 years. On physical examination, CNP notice clubbing of his fingers, use accessory muscles for respiration, wheezing in the lungs, and hyperresonance on percussion of the lungs, and also pulmonary function studies show an FEV1 of 58%. These all symptoms and history represented here most strongly indicate the probability of chronic obstructive pulmonary disease (COPD). COPD is a respiratory disease categorized by chronic airway inflammation, a decrease in lung function over time, and gradual damage in quality of life (Booker, 2014).

COPD is one of the greatest causes of disability and mortality in the twenty first century with future predictions painting an even graver story. Occupation, genome, and primarily smoking are the main causes of COPD. COPD is the third leading cause of death in America, claiming the lives of 134,676 Americans in 2010. Symptoms are typical of a constant smokers cough which progresses into the debilitating palliative stage of the disease; the development of co-morbidities exacerbates these symptoms. COPD has a complex pathophysiology involving hyperinflation, excessive mucus production and airway remodeling; diagnosis is through lung function tests. COPD is poorly managed with few effective treatments and a poor

Have you ever known a person who smokes and has a hard time doing every day activities, due to difficulty of breath, or constantly coughing. He or she may have Chronic Obstructive Pulmonary Disease, or COPD. COPD is a progressive and treatable lung disease that causes shortness of breath due to obstruction of air way (COPD, 2013). Progressive means that is gradually gets worse over time. It is a combination of chronic bronchitis and emphysema (Causes,2014). Chronic bronchitis is inflammation of the bronchioles, which causes mucus build up (Davis,2016). Emphysema is when the air sacs get enlarged (Smoking, 2016). Since the disease does not have a cure yet it is important to know pathology (path of disease), epidemiology (who is effected in a population), ethology (who is effected genetically), manifestation (symptoms), treatment, and outcome.

Chronic obstructive pulmonary disease (COPD) is in the top five principal cause of death in the U.S. The disease is an abnormal inflammatory reaction in the lungs with limited airflow. COPD characteristically arises around the age 35. Smoking continues to be the main source of COPD, but is not the only known root cause. In many studies, smoking explanations for at least three fourths of COPD cases ("Chronic obstructive pulmonary disease | University of Maryland Medical Center," n.d.). Stopping smoking has been known to improve lung capabilities and help to prevent death from COPD. Genetic conditions and introductions to airborne toxins, irritants and gasses are correspondingly involved in the growth of the illness. A complete treatment plan could comprise of lifestyle changes, one or more medications, patient education, oxygen therapy respiratory rehabilitation, and surgery ("Chronic obstructive pulmonary disease | University of Maryland Medical Center," n.d.).

An incentive spirometer is a device that our patients use to improve the function of their lungs. This main underlying principle is that breathing can be exercised to train the expansion of lungs capacity (Potter, Perry, Stockert, & Hall, 2013). Patients who qualify for this intervention include those who have recently had a surgery, were under anesthesia, or have been placed on bed rest. Our main concern here is that these situations create opportunity for less activity within the lungs, which can put the patient at risk for pneumonia.

A. has a history of smoking for 50 years and being diagnosed with COPD 2 years ago. Development of COPD and its exacerbations may be a leading caused by bacteria, viruses, or environmental pollutants, including cigarette smoke. Coussa, et al, “Expiratory flow limitation (EFL), as a consequence of airway inflammation is the pathophysiological hallmark of COPD.” Exacerbations fundamentally reflect acute worsening of EFL and there is evidence for both increased airway inflammatory activity and worsening airway obstruction as likely explanations.

2) Asthma (ICD-10-CM-J45). This is a chronic disease that is characterized by difficulty in breathing due to narrowing and swelling of the bronchial airways. Some of the symptoms include shortness of breath, wheezing and coughing. Asthmatic attack can be triggered by dust particles in the air, pollen, stress or exercise (Gillman & Douglass, 2012).

Chronic obstructive pulmonary disease (COPD) is preventable disease that has a detrimental effects on both the airway and lung parenchyma (Nazir & Erbland, 2009). COPD categorises emphysema and chronic bronchitis, both of which are characterised by a reduced maximum expiratory flow and slow but forced emptying of the lungs (Jeffery 1998). The disease has the one of the highest number of fatalities in the developed world due to the ever increasing amount of tobacco smokers and is associated with significant morbidity and mortality (Marx, Hockberger & Walls, 2014). Signs and symptoms that indicate the presence of the disease include a productive cough, wheezing, dyspnoea and predisposing risk factors (Edelman et al., 1992).

How would you describe the pathophysiology of COPD and comorbid heart failure to Charlie, considering that he has no medical knowledge/background?

All over the world, chronic obstructive pulmonary disease (COPD) is a very significant and prevalent cause of morbidity and mortality, and it is increasing with time (Hurd, 2000; Pauwels, 2000; Petty, 2000). Due to the factor of COPD being an underdiagnosed and undertreated disease, the epidemiology (Pauwels, Rabe, 2004) is about 60 to 85 % with mild or moderate COPD remaining undiagnosed (Miravitlles et al., 2009; Hvidsten et al., 2010).

The World Health Organization (WHO) (2006A) defines COPD as a disease state characterized by airflow limitation that is not wholly reversible. The airflow limitation is usually both progressive and associated with abnormal inflammatory response of the lungs to noxious particles or gases. John's chronic bronchitis is defined, clinically, as the presence of a chronic productive cough for 3 months in each of 2 successive years, provided other causes of chronic cough have been ruled out. (Mannino, 2003). The British lung Foundation (BLF) (2005) announces that chronic bronchitis is the inflammation and eventual scarring of the lining of the bronchial tubes which is the explanation for John's dyspnea. The BLF (2005) believe that when the bronchi become inflamed less air is able to flow to and from the lungs and once the bronchial tubes have been irritated over a long period of time, excessive mucus is produced. This increased sputum results from an increase in the size and number of goblet cells (Jeffery, 2001) resulting in John's excessive mucus production. The lining of the bronchial tubes becomes thickened and an irritating cough develops, (Waugh & Grant 2004) which is an additional symptoms that john is experiencing.

Chronic Obstructive Pulmonary Disease, also known as COPD, is the third leading cause of death in the United States. COPD includes extensive lungs diseases such as emphysema, non-reversible asthma, specific forms of bronchiectasis, and chronic bronchitis. This disease restricts the flow of air in and out of the lungs. Ways in which these limitations may occur include the loss of elasticity in the air sacs and throughout the airways, the destruction of the walls between air sacs, the inflammation or thickening of airway walls, or the overproduction of mucus in airways which can lead to blockage. Throughout this paper I am going to explain the main causes, symptoms, diagnosis, and ways to reduce COPD.

Asthma and COPD (chronic obstructive pulmonary disease) are the most common inflammatory diseases of the lung. Asthma is an inflammatory disease of the respiratory tract and characterized by bronchial hyper-reactivity, airway constriction, loss of breath, wheezing and mucus production in the lung. In the world, the number of individuals suffering from asthma is increasing at an alarming rate. About 18.7 million adults and 6.8 million of children in the United States suffer from asthma as reported by CDC (Asthma, n.d.). Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that leads to obstructed airflow from the lungs. Inflammatory response to cigarette smoke is a major cause for the development of chronic obstructive

COPD is characterized by chronic inflammation found in the airways lung parenchyma, and pulmonary vasculature (Huether and McCance, 2012). The pathogenesis of COPD is complex and involves many mechanisms. However, the primary process is inflammation (Huether and McCance, 2012). The inflammatory process starts with inhalation of toxic particles and gases. The airways become inflamed, resulting in excess mucus production; Peripheral ways undergo repeated cycles of injury and repair of the airway walls with resultant structural remodeling (Huether and McCance, 2012). The lungs can be inflated quickly but can only partially deflate.

The relationship between cigarettes and COPD is a respone dose, which means that more smoked cigarettes and longer smoking habits, the risk will be worse. The speed of VEP1 decrease at any time by the number of cigarettes smoked. This study aims to determine the relationship between smoking status of COPD patients with decreased velocity of VEP1. The research method used is retrospective cohort technique with simple random sampling technique. A total of 46 male COPD patients were divided into 2 groups: PPOK patients who were still smoking and had stopped smoking data taken the last 3 years ie 2015, 2016 and 2017 medical record data at Poli Lung RSUD Pasar Rebo. Patients with COPD who still have a faster smoking habit decreased VEP1 of 105 ml